How does the gut microbiome influence immune checkpoint blockade therapy?

Almonte, Andrew A; Rangarajan, Hareesha; Yip, Desmond; Fahrer, Aude M

Almonte, Andrew A; Rangarajan, Hareesha; Yip, Desmond; Fahrer, Aude M.

Affiliation

Almonte AA; Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Acton, ACT, Australia.
Rangarajan H; Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Acton, ACT, Australia.
Yip D; Department of Medical Oncology, The Canberra Hospital and ANU Medical School, Australian National University, Garran, ACT, Australia.
Fahrer AM; Division of Biomedical Science and Biochemistry, Research School of Biology, Australian National University, Acton, ACT, Australia.

Immunol Cell Biol ; 99(4): 361-372, 2021 04.

Article in En | MEDLINE | ID: mdl-33147357

Subject(s)

Gastrointestinal Microbiome; Neoplasms; Animals; Bacteria; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Mice; Neoplasms/drug therapy

Key words

CTLA-4/PD-1/PD-L1; T cells; gut microbiome; immune checkpoint blockade; immunology; immunotherapy; lymphocytes; tumor immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gastrointestinal Microbiome / Neoplasms Limits: Animals / Humans Language: En Journal: Immunol Cell Biol Journal subject: ALERGIA E IMUNOLOGIA Year: 2021 Type: Article Affiliation country: Australia

Fulltext

XML

PubMed Links

Search on Google